KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Net Margin (2018 - 2026)

Aurinia Pharmaceuticals filings provide 8 years of Net Margin readings, the most recent being 273.35% for Q4 2025.

  • On a quarterly basis, Net Margin rose 27096.0% to 273.35% in Q4 2025 year-over-year; TTM through Dec 2025 was 101.46%, a 9902.0% increase, with the full-year FY2025 number at 101.45%, up 9900.0% from a year prior.
  • Net Margin hit 273.35% in Q4 2025 for Aurinia Pharmaceuticals, up from 42.95% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 273.35% in Q4 2025 to a low of 5511.93% in Q1 2021.
  • Median Net Margin over the past 5 years was 26.18% (2023), compared with a mean of 345.75%.
  • Biggest five-year swings in Net Margin: skyrocketed 152025391bps in 2021 and later plummeted -855bps in 2023.
  • Aurinia Pharmaceuticals' Net Margin stood at 142.38% in 2021, then surged by 36bps to 91.6% in 2022, then skyrocketed by 35bps to 59.58% in 2023, then soared by 104bps to 2.39% in 2024, then surged by 11352bps to 273.35% in 2025.
  • The last three reported values for Net Margin were 273.35% (Q4 2025), 42.95% (Q3 2025), and 30.73% (Q2 2025) per Business Quant data.